Thursday 20 September 2018 at 4:00 pm in QCRI 100/01 Conf. Rms.
F. Chris MacPhee Assistant Director (Operations) Centre for Advance Computing @ Queen's
Title: "Secret Identity: CAC, PHI, and You"
Do you have a family doctor in Canada? Have you received medical treatment in Ontario? Do you enjoy going to the movies? If you answered yes to any of the previous questions, your secret identity (aka PHI and PI) already resides at the CAC!
The Centre for Advanced Computing (CAC) @ Queen’s University is your local research IT solution provider. As a university centre, we are mandated to help in the design, implementation, and support of secure, advanced computing solutions for academic and medical clients. A security and privacy focus at CAC enables our partners to meet the strictest regulatory frameworks and standards in Canada and worldwide, facilitating residency of health data from dozens of different hospitals and clinics across in Canada.
We look forward to sharing some great opportunities and resources available to the Queen’s community. Note that capes, masks, and tights not required for the seminar, but are encouraged.
Host: Dr. Lois Mulligan (email@example.com; ext 77475)
Monday 15 October 2018 at 4:00 pm in QCRI 100/01 Conf Rms.
Tricia Cottrell, MD, PhD Chief Resident, Anatomic Pathology (PGY4) Johns Hopkins University School of Medicine (Baltimore, MD)
"Histopathologic features of response and resistance to neoadjuvant anti-PD-1 in non-small cell lung carcinoma (NSCLC)"
Features of the pretreatment tumor microenvironment (TME) are broadly associated with patient prognosis and useful in enriching for subsets of patients likely to respond to immune checkpoint blockade. In the neoadjuvant setting, the post-treatment TME provides an early indicator of a particular patient’s response status and allows investigation of mechanisms underlying primary resistance. We systematically identified the histopathologic features of immune-mediate tumor regression following neoadjuvant anti-PD1 in NSCLC. These features were used to develop a reproducible method for quantifying pathologic response in this setting, known as 'Immune-Related Pathologic Response Criteria' (irPRC). Early data suggests that these criteria may also be useful in other tumor types, possibly representing a pan-cancer tool for pathologic response assessment. Finally, we are using an optimized and validated multiplex immunofluorescence protocol to explore both pretreatment and post treatment tumor specimens to improve predictions of therapeutic response and identify mechanisms of resistance to immune checkpoint blockade.
Thursday 17 January 2019 at 4:00 pm in QCRI 100/01 Conf Rms.
Bethany Monteith Ames, MD, FRCPC Fellow, Canadian Cancer Trials Group Clinical Investigator Program, Queen's University
"Drug-induced Thrombotic microangiopathy with concurrent proteasome inhibitor use in the treatment of multiple myeloma"
Thrombotic microangiopathy (TMA) is a life-threatening clinical syndrome characterized by hemolytic anemia, thrombocytopenia, and microvascular thrombosis resulting in ischemia and organ damage. There are numerous causes of hemolytic anemia with associated thrombocytopenia that may affect patients with cancer, including drug-induced TMA (DITMA). Multiple myeloma (MM) is a neoplasm arising from clonal expansion of malignant plasma cells within the bone marrow. The treatment frequently includes multi-agent immunochemotherapy, often with the use of proteasome inhibitors (PI) such as bortezomib, carfilzomib, or ixazomib. Drug-induced TMA after PI exposure is an increasingly recognized therapeutic complication. This will be emphasized through the description of three novel cases of TMA that have not previously been described in detail. These three illustrative cases occurred after treatment with carfilzomib, cyclophosphamide, and dexamethasone as part of the MCRN003/MYX1 phase 2 clinical trial for relapsed MM.
Thursday 31 January 2019 at 4:00 pm in QCRI 100/01 Conf Rms.
Julian Lum, PhD Senior Scientist, Deeley Research Centre, BC Cancer Agency Associate Professor, University of Victoria
"Metabolic Portraits of Tumor Infiltrating Lymphocytes"
The recent success of cellular immunotherapy (e.g. adoptive T cell therapy and CAR-T cell) for treating hematological malignancies has energized the field to replicate this in epithelial cancers. The lack of clinical responses in solid tumors is poorly understand though metabolic competition between tumors and tumor infiltrating lymphocytes has emerged as an key driver for immune suppression. Using mass spectrometry-based analysis, we are comparing the metabolic profile of human ovarian tumor and T cell samples derived from a matched donor specimen. Our results have uncovered distinct metabolic portraits that can serve as targets to enhance T cell-based therapies.
Bio: Dr. Lum is a Senior Scientist at BC Cancer, and Associate Professor at the University of Victoria. He completed his PhD at the University of Ottawa and moved to the University of Pennsylvania for his post-doc studies where he contributed seminal findings to the field of autophagy regulation. He returned to Canada and established his laboratory in Victoria where he has continued his long-standing interest in how cells adapt to metabolic stress and how this could inform new strategies to enhance T cell immunotherapy. Dr. Lum’s group is involved in translational and clinical research in ovarian and prostate cancer, where he has applied his basic research discoveries to launch clinical trials in these disease sites.